Suggested remit: To appraise the clinical and cost effectiveness of glycopyrronium bromide cream within its marketing authorisation for treating severe primary axillary hyperhidrosis.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6487
Provisional Schedule
- Draft guidance:
- 14 November 2025 - 05 December 2025
- Committee meeting: 2:
- 14 January 2026
- Expected publication:
- 11 March 2026
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
- External Assessment Group:
- BMJ Technology Assessment Group (BMJ-TAG), BMJ
Stakeholders
- Companies sponsors
- Leith Healthcare
- Others
- Department of Health and Social Care
- NHS England
- NHS Cornwall and Isles of Scilly ICB
- Patient carer groups
- Hyperhidrosis UK
- Professional groups
- British Association of Dermatologists
- Royal College of Physicians
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Abbvie (botulinum toxin type A) - not participating
- Aspire Pharma (prolonged-release oxybutynin) - not participating
- Croma Pharma (botulinum toxin type A)- not participating
- Dawa (glycopyrronium bromide) - not participating
- Evolus International (botulinum toxin type A) - not participating
- Galderma (botulinum toxin type A) - not participating
- Grünenthal Meds (propantheline bromide)
- Merz Aesthetics (botulinum toxin type A) - not participating
- Morningside Healthcare (glycopyrronium bromide) - not participating
- Neon Healthcare (oxybutynin) - not participating
- Tillomed laboratories (oxybutynin) - not participating
- Strandhaven Limited t/a Somex Pharma (glycopyrronium bromide) - not participating
- Strides Pharma (oxybutynin) - not participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- Scottish Medicines Consortium
- Welsh Government
- Welsh Health Specialised Services Committee
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 October 2025 | Committee meeting |
| 08 October 2025 | Declaration of interests |
| 16 April 2025 | Referral |
| 10 March 2025 | Invitation to participate |
| 04 February 2025 (00:00) | Scoping workshop |
| 05 December 2024 - 14 January 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6487 |
| 12 December 2024 | Referral |
| 05 December 2024 | In progress. Scoping commenced. |
| 16 September 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual